 The aim of the study is to assess the health-related quality of life HRQOL and preference-based health utilities of chronic hepatitis B CHB carriers in different stages of illness. It will also estimate the cost-effectiveness of anti-viral treatments resulting from the prevention of the progression of disease from uncomplicated CHB carriers to cirrhosis and hepatocellular carcinoma HCC. 